| 1901 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Spain
|
67 |
| 1902 |
Apheresis |
Allogeneic
|
Hemophagocytic Lymphohistiocytosis
|
Hematology
|
2024
|
Standard Therapy
|
United Kingdom
|
48 |
| 1903 |
Apheresis |
Allogeneic
|
Non-Hodgkin’s lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
NETHERLANDS
|
61 |
| 1904 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
29 |
| 1905 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1906 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Israel
|
63 |
| 1907 |
Apheresis |
Allogeneic
|
ETP-Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
35 |
| 1908 |
Apheresis |
Allogeneic
|
Hodgkin lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
4 |
| 1909 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
23 |
| 1910 |
Apheresis |
Allogeneic
|
Fanconi Anemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
27 |
| 1911 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
69 |
| 1912 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
44 |
| 1913 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
49 |
| 1914 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
20 |
| 1915 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
France
|
50 |
| 1916 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
74 |
| 1917 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Austria
|
49 |
| 1918 |
Apheresis |
Allogeneic
|
Post-PV Myelofibrose
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
59 |
| 1919 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
66 |
| 1920 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
58 |
| 1921 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
55 |
| 1922 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy
|
France
|
70 |
| 1923 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
France
|
54 |
| 1924 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
68 |
| 1925 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
41 |
| 1926 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
31 |
| 1927 |
Apheresis |
Allogeneic
|
Other leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Italy
|
31 |
| 1928 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Sweden
|
42 |
| 1929 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
43 |
| 1930 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
52 |
| 1931 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
64 |
| 1932 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
60 |
| 1933 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
70 |
| 1934 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
65 |
| 1935 |
Apheresis |
Allogeneic
|
Primary myelofibrosis
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
55 |
| 1936 |
Apheresis |
Autologous
|
Amyloid Light-Chain Amyloidosis
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
55 |
| 1937 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
61 |
| 1938 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
65 |
| 1939 |
Apheresis |
Autologous
|
Epstein–Barr Virus Positive Diffuse Large B-Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
63 |
| 1940 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
69 |
| 1941 |
Apheresis |
Autologous
|
Angioimmunoblastic T-cell lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
58 |
| 1942 |
Apheresis |
Allogeneic
|
Acute lymphoblastic leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
19 |
| 1943 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
66 |
| 1944 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
61 |
| 1945 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Canada
|
16 |
| 1946 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
61 |
| 1947 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
75 |
| 1948 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
62 |
| 1949 |
Apheresis |
Allogeneic
|
Myelodysplastic Disorders
|
Hematology
|
2024
|
Standard Therapy
|
France
|
66 |
| 1950 |
Apheresis |
Allogeneic
|
B-Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Canada
|
70 |
| 1951 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Italy
|
60 |
| 1952 |
Apheresis |
Allogeneic
|
Myeloma Multiplex
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
57 |
| 1953 |
Apheresis |
Allogeneic
|
Diffuse large B-cell lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
17 |
| 1954 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
48 |
| 1955 |
Apheresis |
Allogeneic
|
Chronic lymphocytic leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
63 |
| 1956 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
65 |
| 1957 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
64 |
| 1958 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
76 |
| 1959 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
44 |
| 1960 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1961 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
NETHERLANDS
|
25 |
| 1962 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
42 |
| 1963 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
CROATIA
|
66 |
| 1964 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
70 |
| 1965 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Switzerland
|
68 |
| 1966 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukaemia
|
Hematology
|
2024
|
Standard Therapy
|
NETHERLANDS
|
62 |
| 1967 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
58 |
| 1968 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
62 |
| 1969 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Belarus
|
54 |
| 1970 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Spain
|
9 |
| 1971 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
66 |
| 1972 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
France
|
67 |
| 1973 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
France
|
54 |
| 1974 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
South Africa
|
54 |
| 1975 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
60 |
| 1976 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Sweden
|
60 |
| 1977 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Spain
|
67 |
| 1978 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
66 |
| 1979 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
53 |
| 1980 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
65 |
| 1981 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma, rezidiv
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
64 |
| 1982 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
57 |
| 1983 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
66 |
| 1984 |
Apheresis |
Allogeneic
|
Acute lymphoblastic leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
50 |
| 1985 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
57 |
| 1986 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
70 |
| 1987 |
Apheresis |
Allogeneic
|
Multiple Organ Dysfunction Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
42 |
| 1988 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
32 |
| 1989 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
76 |
| 1990 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Italy
|
63 |
| 1991 |
Apheresis |
Allogeneic
|
Early T-cell precursor Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Australia
|
43 |
| 1992 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
72 |
| 1993 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
72 |
| 1994 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
52 |
| 1995 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
73 |
| 1996 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
68 |
| 1997 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Italy
|
63 |
| 1998 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Czechia
|
46 |
| 1999 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
France
|
64 |
| 2000 |
Apheresis |
Allogeneic
|
Primary Immunodeficiencies
|
Hematology
|
2024
|
Standard Therapy
|
Russia
|
7 |